Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

CNS Appoints Leading Toxicologist Douglas Francis to BioDesk

Published: Monday, March 04, 2013
Last Updated: Monday, March 04, 2013
Bookmark and Share
Dr Francis appointed as Senior Regulatory Toxicologist to the Company’s product development planning and regulatory affairs service.

Clinical Network Services (CNS) has announced that it has appointed ex-Therapeutic Goods Administration (TGA) toxicologist, Dr Douglas Francis, as Senior Regulatory Toxicologist to the Company’s BioDesk product development planning and regulatory affairs service.

In his new role, Dr Francis will be providing advice and assistance to international and Australian/New Zealand biotechnology companies in the areas of toxicology, pharmacology, and drug optimization in support of the conduct of clinical trials and drug registration in key global markets.

Dr Francis is a UK/European registered toxicologist and is a member of a number of international bodies including the US Society of Toxicology (SOT) by review, the American College of Toxicology (ACT), the British Toxicology Society (BTS) and the Roundtable of Toxicology Consultants.

He originally studied Veterinary Science at the University of Sydney followed by a PhD at the University of Sydney and was, for a number of years, a clinical academic at the University of Sydney and the University of Melbourne.

Most recently, Dr Francis offered regulatory toxicology services to small to medium pharmaceutical and biotech clients in Australia, Europe and the USA through his own consultancy, DF Pre-clinical Services Pty Ltd.

Previous to that, he was the Vice President of Drug Development for the Australian biotechnology company, Phylogica Pty Ltd, and from 1998-2006, Drug Development Manager at Pharmaxis Ltd where he managed many of the company’s pre-clinical programs.

This latter role led to him to gain worldwide product marketing authorizations for these programs in key global markets. Dr Francis was a Senior Toxicologist at the TGA from 1995-1997, and was part of a research team at the John Curtin School of Medical Research, Australian National University, Canberra, Australia from 1998-2001.

Mark Reid, Associate Director, BioDesk & Regulatory Affairs, commented: “Dr Francis is arguably the most qualified senior toxicologist for drug development in Australia and has global regulatory toxicological experience in the key pharmaceutical markets of Europe and the USA. We have been working with Doug for a number of years now on a consultancy basis and are looking forward to the merging of his consultancy operations with the BioDesk operation of CNS”.

Mark Ried will be attending the DIA EuroMeeting 2013 in Amsterdam, the Netherlands from the 4th to 6th March and BIOEurope Spring 2013 in Barcelona, Spain on 11th to 13th March 2013.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Rates of Nonmedical Prescription Opioid Use Disorder Double in 10 Years
Researchers at NIH have found that the nonmedical use of prescription opioids has more than doubled among adults in the United States from 2001-2002 to 2012-2013.
Self-Assembling Protein Shell for Drug Delivery
Made-to-order nano-cages open possibilities of shipping cargo into living cells or fashioning small chemical reactors.
Guided Chemotherapy Missiles
Latching chemotherapy drugs onto proteins that seek out tumors could provide a new way of treating tumors in the brain or with limited blood supply that are hard to reach with traditional chemotherapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
‘Human-on-a-Chip’ Could Replace Animal Testing
Researchers are developing a “human-on-a-chip,” a miniature external replication of the human body, integrating biology and engineering with a combination of microfluidics and multi-electrode arrays.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
‘Missing Tooth’ Hydrogels Handle Hard-to-Deliver Drugs
Rice University’s custom hydrogel traps water-avoiding molecules for slow delivery.
Copper is Key in Burning Fat
Berkeley Lab scientist says results could provide new target for obesity research.
Better Animal Model to Improve HIV Vaccine Development
Penn study identifies a new tool to produce better HIV vaccine designs.
Identifying Side-Effects At Early Stages Of Drug Development
An approach that could reduce the chances of drugs failing during the later stages of clinical trials has been demonstrated by a collaboration between the University of Cambridge and pharmaceutical company GlaxoSmithKline (GSK).
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!